{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:15:47Z","timestamp":1772165747330,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,3]],"date-time":"2020-04-03T00:00:00Z","timestamp":1585872000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,4,3]],"date-time":"2020-04-03T00:00:00Z","timestamp":1585872000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Detection of epidermal growth factor receptor (\n                      <jats:italic>EGFR)<\/jats:italic>\n                      mutations in exons 18\u201321 is recommended in all patients with advanced Non-small-cell lung carcinoma due to the demonstrated efficiency of the standard therapy with tyrosine kinase inhibitors in\n                      <jats:italic>EGFR<\/jats:italic>\n                      -mutated patients. Therefore, choosing a suitable technique to test\n                      <jats:italic>EGFR<\/jats:italic>\n                      mutational status is crucial to warrant a valid result in a short turnaround time using the lowest possible amount of tissue material.\n                    <\/jats:p>\n                    <jats:p>\n                      The Idylla\u2122\n                      <jats:italic>EGFR<\/jats:italic>\n                      Mutation Test is a simple, fast and reliable method designed for the detection of\n                      <jats:italic>EGFR<\/jats:italic>\n                      mutations from formalin-fixed paraffin-embedded samples.\n                    <\/jats:p>\n                    <jats:p>The aim of this study was the Clinical Performace Evaluation of the Idylla\u2122 EGFR Mutation Test on the Idylla\u2122 System.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      <jats:italic>EGFR<\/jats:italic>\n                      mutational status was determined on 132 archived formalin-fixed paraffin-embedded tissue sections with Idylla\u2122 technology. Results were compared with the results previously obtained by routine method in the reference lab (Therascreen\u00ae\n                      <jats:italic>EGFR<\/jats:italic>\n                      RGQ PCR v2, Qiagen in Molecular Pathology lab, Hospital Universitario Virgen del Roc\u00edo de Sevilla).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The overall agreement between results obtained with the Idylla\u2122\n                      <jats:italic>EGFR<\/jats:italic>\n                      Mutation Test and the Comparator test method was 95.38% (with 1-sided 95% lower limit of 91.7%) showing Positive Diagnostic Agreement of 93.22% and Negative Diagnostic Agreement of 97.18%, with a Limit Of Detection \u22645%.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      The Idylla\u2122\n                      <jats:italic>EGFR<\/jats:italic>\n                      Mutation Test passed its clinical validity performance characteristics for accuracy.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-020-6697-7","type":"journal-article","created":{"date-parts":[[2020,4,3]],"date-time":"2020-04-03T10:02:49Z","timestamp":1585908169000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Clinical performance evaluation of the Idylla\u2122 EGFR Mutation Test on formalin-fixed paraffin-embedded tissue of non-small cell lung cancer"],"prefix":"10.1186","volume":"20","author":[{"given":"Mercedes","family":"Delgado-Garc\u00eda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Birgit","family":"Weynand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lourdes","family":"G\u00f3mez-Izquierdo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Jos\u00e9","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1ngela Mar\u00eda","family":"Blanco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar","family":"Varela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Matias-Guiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ernest","family":"Nadal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B\u00e9lgica","family":"M\u00e1rquez-Lobo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Alarc\u00e3o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrique","family":"de \u00c1lava","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4258-6161","authenticated-orcid":false,"given":"Michele","family":"Biscuola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,4,3]]},"reference":[{"issue":"4","key":"6697_CR1","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/S2213-2600(15)00029-6","volume":"3","author":"N Navani","year":"2015","unstructured":"Navani N, Nankivell M, Lawrence DR, et al. Lung cancer diagnosis and staging with endobronchial ultrasound-guided transbronchial needle aspiration compared with conventional approaches: an open-label, pragmatic, randomised controlled trial. Lancet Respir Med. 2015;3(4):282\u20139.","journal-title":"Lancet Respir Med"},{"key":"6697_CR2","volume-title":"Global Cancer Facts & Figures 2nd edition","author":"American Cancer Society","year":"2011","unstructured":"American Cancer Society. Global Cancer Facts & Figures 2nd edition. Atlanta: American Cancer Society; 2011."},{"issue":"4","key":"6697_CR3","doi-asserted-by":"publisher","first-page":"271","DOI":"10.3322\/caac.21349","volume":"66","author":"KD Miller","year":"2016","unstructured":"Miller KD, Siegel RL, Lin CC, et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016;66(4):271\u201389.","journal-title":"CA Cancer J Clin"},{"key":"6697_CR4","unstructured":"Midha A, Dearden S, Mc Cormack R. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: A systematic review and global map by ethnicity (mutMapII). Am J Cancer Res. 2015;5(9):2892\u2013911."},{"issue":"2 Suppl","key":"6697_CR5","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ijrobp.2003.11.041","volume":"59","author":"RS Herbst","year":"2004","unstructured":"Herbst RS. Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys. 2004;59(2 Suppl):21\u20136.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"6697_CR6","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.semcancer.2004.04.005","volume":"14","author":"Y Mosesson","year":"2004","unstructured":"Mosesson Y, Yarden Y. Oncogenic growth factor receptors: implications for signal transduction therapy. Semin Cancer Biol. 2004;14(4):262\u201370.","journal-title":"Semin Cancer Biol"},{"issue":"11","key":"6697_CR7","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1056\/NEJMra0707704","volume":"358","author":"F Ciardiello","year":"2008","unstructured":"Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med. 2008;358(11):1160\u201374.","journal-title":"N Engl J Med"},{"issue":"7511","key":"6697_CR8","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nature13385","volume":"511","author":"Cancer Genome Atlas Research Network","year":"2014","unstructured":"Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014;511(7511):543\u201350.","journal-title":"Nature"},{"issue":"2","key":"6697_CR9","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.jmoldx.2017.11.004","volume":"20","author":"NI Lindeman","year":"2018","unstructured":"Lindeman NI, Cagle PT, Aisner DL, et al. Updated molecular testing guideline for the selection of lung Cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. J Mol Diagn. 2018;20(2):129\u201359.","journal-title":"J Mol Diagn"},{"key":"6697_CR10","doi-asserted-by":"crossref","unstructured":"NCCN Guidelines Version 4. 2019 Non-small cell lung cancer.","DOI":"10.1007\/s10330-018-0325-5"},{"issue":"suppl 5","key":"6697_CR11","doi-asserted-by":"publisher","first-page":"v1","DOI":"10.1093\/annonc\/mdw326","volume":"27","author":"S Novello","year":"2016","unstructured":"Novello S, Barlesi F, Califano R, et al. Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v1\u2013v27.","journal-title":"Ann Oncol"},{"issue":"S5","key":"6697_CR12","first-page":"S479","volume":"5","author":"WA Cooper","year":"2013","unstructured":"Cooper WA, Lam DC, O'Toole SA, Minna JD. Molecular biology of lung cancer. J Thorac Dis. 2013;5(S5):S479\u201390.","journal-title":"J Thorac Dis"},{"issue":"3","key":"6697_CR13","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","volume":"13","author":"R Rosell","year":"2012","unstructured":"Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13(3):239\u201346.","journal-title":"Lancet Oncol"},{"issue":"4","key":"6697_CR14","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.jtho.2015.12.107","volume":"11","author":"B Klughammer","year":"2016","unstructured":"Klughammer B, Brugger W, Cappuzzo F, et al. Examining treatment outcomes with Erlotinib in patients with advanced non-small cell lung Cancer whose Tumors Harbor uncommon EGFR mutations. J Thorac Oncol. 2016;11(4):545\u201355.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"6697_CR15","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s13045-016-0290-1","volume":"9","author":"S Wang","year":"2016","unstructured":"Wang S, Tsui ST, Liu C, Song Y, Liu D. EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer. J Hematol Oncol. 2016;9(1):59.","journal-title":"J Hematol Oncol"},{"issue":"3","key":"6697_CR16","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.yexmp.2015.09.004","volume":"99","author":"L Melchior","year":"2015","unstructured":"Melchior L, Grauslund M, Bellosillo B, et al. Multi-center evaluation of the novel fully-automated PCR-based Idylla\u2122 BRAF mutation test on formalin-fixed paraffin-embedded tissue of malignant melanoma. Exp Mol Pathol. 2015;99(3):485\u201391.","journal-title":"Exp Mol Pathol"},{"issue":"9","key":"6697_CR17","doi-asserted-by":"publisher","first-page":"e0163444","DOI":"10.1371\/journal.pone.0163444","volume":"11","author":"J Solassol","year":"2016","unstructured":"Solassol J, Vendrell J, M\u00e4rkl B, et al. Multi-center evaluation of the fully automated PCR-based Idylla\u2122 KRAS mutation assay for rapid KRAS mutation status determination on formalin-fixed paraffin-embedded tissue of human colorectal Cancer. PLoS One. 2016;11(9):e0163444.","journal-title":"PLoS One"},{"issue":"8","key":"6697_CR18","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1002\/(SICI)1097-0258(19980430)17:8<873::AID-SIM779>3.0.CO;2-I","volume":"17","author":"RG Newcombe","year":"1998","unstructured":"Newcombe RG. Interval estimation for the difference between independent proportions: comparison of eleven methods. Stat Med. 1998;17(8):873\u201390.","journal-title":"Stat Med"},{"issue":"2","key":"6697_CR19","first-page":"126","volume":"4","author":"C Khoo","year":"2015","unstructured":"Khoo C, Rogers TM, Fellowes A, Bell A, Fox S. Molecular methods for somatic mutation testing in lung adenocarcinoma: EGFR and beyond. Transl Lung Cancer Res. 2015;4(2):126\u201341.","journal-title":"Transl Lung Cancer Res"},{"issue":"12","key":"6697_CR20","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1080\/14737159.2016.1248414","volume":"16","author":"EH Hsiue","year":"2016","unstructured":"Hsiue EH, Lee JH, Lin CC, Yang JC. Profile of the Therascreen\u00ae EGFR RGQ PCR kit as a companion diagnostic for gefitinib in non-small cell lung cancer. Expert Rev Mol Diagn. 2016;16(12):1251\u20137.","journal-title":"Expert Rev Mol Diagn"},{"key":"6697_CR21","unstructured":"IASLC Atlas of EGFR testing in Lung Cancer. Mok T S, Carbone D P, Hirsch F R. Editorial Rx Press, North Fort Myers, FL, U.S.A. (2017) ISBN: 978\u20131\u2013947768-00-0."},{"issue":"29","key":"6697_CR22","doi-asserted-by":"publisher","first-page":"26886","DOI":"10.18632\/oncotarget.4723","volume":"6","author":"F Janku","year":"2015","unstructured":"Janku F, Claes B, Huang HJ, et al. BRAF mutation testing with a rapid, fully integrated molecular diagnostics system. Oncotarget. 2015;6(29):26886\u201394.","journal-title":"Oncotarget."},{"issue":"1","key":"6697_CR23","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s12885-017-3112-0","volume":"17","author":"C Weyn","year":"2017","unstructured":"Weyn C, Van Raemdonck S, Dendooven R, et al. Clinical performance evaluation of a sensitive, rapid low-throughput test for KRAS mutation analysis using formalin-fixed, paraffin-embedded tissue samples. BMC Cancer. 2017;17(1):139.","journal-title":"BMC Cancer"},{"issue":"7","key":"6697_CR24","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1136\/jclinpath-2017-204356","volume":"70","author":"R Colling","year":"2017","unstructured":"Colling R, Wang LM, Soilleux E. Validating a fully automated real-time PCR-based system for use in the molecular diagnostic analysis of colorectal carcinoma: a comparison with NGS and IHC. J Clin Pathol. 2017;70(7):610\u20134.","journal-title":"J Clin Pathol"},{"issue":"3","key":"6697_CR25","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1136\/jclinpath-2016-204025","volume":"70","author":"MK Yeo","year":"2017","unstructured":"Yeo MK, Jung MK, Lee SY, Hur GM, Kim JM. The usefulness of a novel fully automated PCRbased Idylla test for detection of the BRAF V600E mutation in thyroid tissue: comparison with PNA-clamping PCR, real-time PCR and pyrosequencing. J Clin Pathol. 2017;70(3):260\u20135.","journal-title":"J Clin Pathol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-6697-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-020-6697-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-6697-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T09:35:28Z","timestamp":1695980128000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-020-6697-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,3]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["6697"],"URL":"https:\/\/doi.org\/10.1186\/s12885-020-6697-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.13180\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.13180\/v3","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.13180\/v1","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,3]]},"assertion":[{"value":"6 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Ethical committee of the Hospital Universitario Virgen del Roc\u00edo with reference 33160034. All patients older than 18 consent to have residual material tested for scientific purposes according to the Spanish legislation of 3 July 2007, unless they stated differently by written agreement.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All the authors declare that no competing interests exist.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"275"}}